1. Home
  2. RDHL vs EVAX Comparison

RDHL vs EVAX Comparison

Compare RDHL & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • EVAX
  • Stock Information
  • Founded
  • RDHL 2009
  • EVAX 2008
  • Country
  • RDHL Israel
  • EVAX Denmark
  • Employees
  • RDHL N/A
  • EVAX N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RDHL Health Care
  • EVAX Health Care
  • Exchange
  • RDHL Nasdaq
  • EVAX Nasdaq
  • Market Cap
  • RDHL 8.2M
  • EVAX 8.7M
  • IPO Year
  • RDHL N/A
  • EVAX 2021
  • Fundamental
  • Price
  • RDHL $5.23
  • EVAX $2.49
  • Analyst Decision
  • RDHL
  • EVAX Strong Buy
  • Analyst Count
  • RDHL 0
  • EVAX 3
  • Target Price
  • RDHL N/A
  • EVAX $33.33
  • AVG Volume (30 Days)
  • RDHL 10.4K
  • EVAX 6.9M
  • Earning Date
  • RDHL 04-07-2025
  • EVAX 03-26-2025
  • Dividend Yield
  • RDHL N/A
  • EVAX N/A
  • EPS Growth
  • RDHL N/A
  • EVAX N/A
  • EPS
  • RDHL N/A
  • EVAX N/A
  • Revenue
  • RDHL $3,707,000.00
  • EVAX $3,295,000.00
  • Revenue This Year
  • RDHL $224.90
  • EVAX $9,039.73
  • Revenue Next Year
  • RDHL $82.69
  • EVAX $1.47
  • P/E Ratio
  • RDHL N/A
  • EVAX N/A
  • Revenue Growth
  • RDHL N/A
  • EVAX N/A
  • 52 Week Low
  • RDHL $5.20
  • EVAX $2.22
  • 52 Week High
  • RDHL $20.28
  • EVAX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 31.92
  • EVAX 39.85
  • Support Level
  • RDHL $5.52
  • EVAX $2.30
  • Resistance Level
  • RDHL $5.71
  • EVAX $2.80
  • Average True Range (ATR)
  • RDHL 0.27
  • EVAX 0.51
  • MACD
  • RDHL -0.04
  • EVAX 0.03
  • Stochastic Oscillator
  • RDHL 2.38
  • EVAX 6.97

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

About EVAX Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Share on Social Networks: